Quest for the right Drug

|
עמוד הבית / אוליקלינומל N4-550E / מידע מעלון לרופא

אוליקלינומל N4-550E OLICLINOMEL N4-550E (CALCIUM CHLORIDE DIHYDRATE, GLUCOSE AS MONOHYDRATE, GLYCINE, L- ALANINE, L- ISOLEUCINE, L- LEUCINE, L- LYSINE AS HYDROCHLORIDE, L- METHIONINE, L- PHENYLALANINE, L- PROLINE, L- SERINE, L- THREONINE, L- TRYPTOPHAN, L- TYROSINE, L- VALINE, L-ARGININE, L-HISTIDINE, MAGNESIUM CHLORIDE HEXAHYDRATE, POTASSIUM CHLORIDE, REFINED SOYA-BEAN OIL, SODIUM ACETATE TRIHYDRATE, SODIUM GLYCEROPHOSPHATE PENTAHYDRATE)

תרופה במרשם תרופה בסל נרקוטיקה ציטוטוקסיקה

צורת מתן:

תוך-ורידי : I.V

צורת מינון:

תחליב לאינפוזיה : EMULSION FOR INFUSION

Interactions : אינטראקציות

4.5. Interaction with other medicinal products and other forms of interaction
No interaction studies have been performed

Ceftriaxone must not be administered simultaneously with intravenous calcium-containing solutions, including Oliclinomel, through the same infusion line because of the risk of precipitation of ceftriaxone- calcium salt.

If the same infusion line is used for sequential administration, the line must be thoroughly flushed between infusions with a compatible fluid (e.g. physiological salt solution) to avoid precipitation 
Oliclinomel contains vitamin K, naturally present in lipid emulsions. The amounts of Vitamin K in recommended doses of Oliclinomel, are not expected to influence effects of coumarin derivatives.

This emulsion for infusion must not be administered simultaneously with blood through the same infusion tubing because of the possibility of pseudoagglutination.
The lipids contained in this emulsion may interfere with the results of certain laboratory tests (for example, bilirubin, lactate dehydrogenase, oxygen saturation, blood haemoglobin) if the blood sample is taken before the lipids have been eliminated (these are generally eliminated after a period of 5 to 6 hours without receiving lipids).
Oliclinomel N4-550E,             9 6. 2015, RH             Page 6 sur 14 

Due to the potassium content of Oliclinomel, special care should be taken in patients treated with potassium- sparing diuretics (e.g, amiloride, spironolactone, triamterene) angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists or the immunosuppressants tacrolimus and cyclosporine in view of the risk of hyperkalemia.

שימוש לפי פנקס קופ''ח כללית 1994 לא צוין
תאריך הכללה מקורי בסל לא צוין
הגבלות לא צוין

בעל רישום

TEVA MEDICAL MARKETING LTD.

רישום

139 38 30706 21

מחיר

0 ₪

מידע נוסף

עלון מידע לרופא

16.06.15 - עלון לרופא

עלון מידע לצרכן

07.06.15 - עלון לצרכן 11.03.12 - החמרה לעלון

לתרופה במאגר משרד הבריאות

אוליקלינומל N4-550E

קישורים נוספים

RxList WebMD Drugs.com